US 12,612,442 B2 · G12-specific designer receptor exclusively activated by designer drugs

Abstract

Disclosed is a Designer Receptor Exclusively Activated by Designer Drugs (DREADD), and an amino acid sequence for determining coupling or no coupling between G-protein and G-protein coupled receptor (GPCR) mediated by a GPCR ligand in a cell based assay.

Claims1

Dependent claims

A Designer Receptor Exclusively Activated by Designer Drugs (DREADD), wherein the DREADD is a G12-specific G-protein coupled receptor (GPCR) responding to a ligand and comprises or consists of the amino acid sequence SEQ ID NO:

2, 3 or 4.

Dependencies are inferred from the claim text.

Facts

Application

17/615,000Filed 29 May 2020

Priority

EP 1917738729 May 2019

Published

US 2022/0220185 A114 Jul 2022

Granted

28 Apr 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07K 14/705
From animals; from humans: receptors; Cell surface antigens; Cell surface determinants
G16B 15/30
ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations…:…
C12N 9/12
Transferases: transferring phosphorus containing groups, e.g. kinases
C12N 9/14
Enzymes; Proenzymes; Compositions thereof ; Processes for preparing, activating, inhibiting, separating or purifying enzymes: hydrolases

G12-specific designer receptor exclusively activated by designer drugs

Life of this patent

Abstract

Claims1

G12-specific designer receptor exclusively activated by designer drugs

Life of this patent

Abstract

Claims1